Tumour necrosis is a valuable histopathological prognostic parameter in melanomas of the vulva and vagina.

Breslow Vulvar melanoma prognosis tumour necrosis vaginal melanoma vulvovaginal melanoma

Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
28 May 2024
Historique:
received: 11 10 2023
revised: 03 03 2024
accepted: 25 03 2024
medline: 22 6 2024
pubmed: 22 6 2024
entrez: 21 6 2024
Statut: aheadofprint

Résumé

Vulvar and vaginal melanomas (VVMs) are rare and aggressive malignancies with limited prognostic models available and there is no standard reporting protocol. VVMs were selected from six tertiary Canadian hospitals from 2000-2021, resected from patients aged ≥18 years, with 6 months or longer follow-up data, and confirmation of melanocytic differentiation by at least two immunohistochemical markers. Cases were reviewed by pathologists to identify histological biomarkers. Survival outcomes were tested with Kaplan-Meier log-rank, univariate Cox, and multivariate Cox regression. There were 79 VVMs with median follow-up at 26 months. Univariate analysis revealed that tumour necrosis, tumour ulceration, positive lymph nodes, and metastasis at diagnosis were significantly associated with disease-specific mortality, progression, and metastasis. Multivariate analysis identified tumour necrosis as an independent prognostic factor for disease-specific mortality (HR 4.803, 95% CI 1.954-11.803, p<0.001), progression (HR 2.676, 95% CI 1.403-5.102, p=0.003), and time-to-metastasis for non-metastatic patients at diagnosis (HR 3.761, 95%CI 1.678-8.431, p=0.001). Kaplan-Meier survival analyses demonstrated that tumour necrosis was a poor prognostic factor for disease-specific, progression-free, and metastasis-free survival (p<0.001 for all comparisons). Vaginal melanomas displayed decreased survival compared to vulvar or clitoral melanomas. This study identifies tumour necrosis as an independent prognostic factor for VVMs. Vaginal melanomas specifically showed worse survival outcomes compared to vulvar or clitoral melanomas, consistent with previously reported findings in the literature, emphasising the importance of differentiating between these primary tumour epicentres for prognostication and treatment planning in the care of genital melanoma patients.

Identifiants

pubmed: 38906758
pii: S0031-3025(24)00136-3
doi: 10.1016/j.pathol.2024.03.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Auteurs

Simon F Roy (SF)

Department of Dermatology, Yale School of Medicine, New Haven, USA. Electronic address: Simon.roy@yale.edu.

Jumanah Baig (J)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Canada.

Ryan DeCoste (R)

Department of Pathology, Dalhousie University, Halifax, Canada.

Sarah Finch (S)

Department of Pathology, Memorial University of Newfoundland, St-John's, Canada.

Simrin Sennik (S)

Department of Pathology, Memorial University of Newfoundland, St-John's, Canada.

Archana Kakadekar (A)

Department of Pathology, University of Saskatchewan, Regina, Canada.

Shachar Sade (S)

Department of Pathology, University of Toronto, Toronto, Canada.

Goran Micevic (G)

Department of Dermatology, Yale School of Medicine, New Haven, USA.

May Chergui (M)

Department of Pathology, McGill University, Montreal, Canada.

Kurosh Rahimi (K)

Department of Pathology and Cellular Biology, University of Montreal, Montreal, Canada.

Ashley Flaman (A)

Department of Pathology, University of Calgary, Calgary, Canada.

Vincent Q H Trinh (VQH)

Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Canada.

Allison Osmond (A)

Department of Pathology, University of Saskatchewan, Regina, Canada.

Classifications MeSH